18:16 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda...
11:02 , Aug 20, 2018 |  BC Extra  |  Financial News

Real-world data play RDMD raises $3M seed round

RDMD (San Francisco, Calif.) raised $3 million in a seed round led by new investor Lux Capital, with participation from existing investor Village Globe and new investors First Round's Healthcare Co-Op, Garuda and Shasta Ventures. Several...
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
07:00 , Jun 13, 2016 |  BioCentury  |  Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Neurofibromin 1 (NF1)

Cancer INDICATION: Neurofibromatosis Mouse studies suggest MEK inhibitors could help treat neurofibromatosis type 1, which is caused by loss-of-function mutations in the tumor suppressor gene NF1. In neonatal mice with neuronal precursor-specific knockout of NF1, treatment...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Neurofibromin 1 (NF1); MEK; suppressor of zeste 12 homolog (SUZ12); bromodomain containing 4 (BRD4) ...